Revvity Expands Newborn Screening Mass Spectrometry Offering Through SCIEX Partnership
Revvity, Inc. has taken a significant stride towards enhancing newborn screening with a new distribution agreement with SCIEX, a global leader in life science analytical technologies. This strategic collaboration aims to advance mass spectrometry solutions within Revvity’s newborn screening products, focusing on the early detection of rare disorders in newborns.
Mass spectrometry, an essential tool in expanded newborn screening, has witnessed remarkable growth in recent years. Revvity, in conjunction with SCIEX, will integrate SCIEX mass spectrometers with Revvity’s NeoBase™ 2 and NeoLSD™ reagents to further bolster the company’s offerings for mass spectrometry analyses for newborn screening.
The Advisory Committee on Heritable Disorders in Newborns and Children issues a Recommended Universal Screening Panel that identifies a number of core conditions—those for which screening is highly recommended—and secondary conditions, for which screening is optional. Tandem mass spectrometry is used in newborn screening and complements existing methods and is used to analyze dried blood filter paper specimens collected from newborn infants. Mass spectrometry utilizes special instruments to analyze the dried blood spot specimens for specific metabolites that are produced during the metabolism of proteins and fats. MS/MS screening is utilized to detect amino acid, organic acid and fatty acid oxidation disorders. Elevated levels of these amino acids may signal a newborn’s susceptibility to amino acid metabolism disorders. The primary goal of screening is to detect rare but treatable conditions, such as lysosomal storage disorders, in newborns as early as possible.
Tests for newborn disorders are typically ran at state labs on dried blood spot samples and every year in the United States there are approximately 4 million newborns that require screening. The overall market in the U.S. is estimated at about $100 million per year. Perkin Elmer and Waters Corp. are leaders in this market.
Petra Furu, General Manager of Reproductive Health at Revvity, emphasized their commitment to advancing newborn screening and offering babies a better start in life. This strategic partnership aims to empower customers with precise instrumentation and groundbreaking reagents to bolster their expanded screening programs.